NovoCure (NVCR) Income towards Parent Company (2014 - 2026)

NovoCure has disclosed Income towards Parent Company across 13 years of filings, most recently posting -$15.7 million for Q2 2026.

• In Q2 2026, Income towards Parent Company rose 60.99% year-over-year to -$15.7 million; the TTM figure through Jun 2026 stood at -$148.6 million (up 13.09% YoY), while the FY2025 annual figure was -$136.2 million, up 19.21% from the prior year.
• Income towards Parent Company came in at -$15.7 million for Q2 2026 at NovoCure, up from -$71.1 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$4.6 million in Q1 2022 to a low of -$71.1 million in Q1 2026.
• Average Income towards Parent Company over 5 years is -$38.4 million, with a median of -$37.3 million recorded in 2022.
• Year-over-year, Income towards Parent Company sank 1041.83% in 2023 and jumped 62.84% in 2025.
• Over 5 years, Income towards Parent Company stood at -$37.3 million in 2022, then dropped by 26.21% to -$47.1 million in 2023, then slumped by 40.02% to -$65.9 million in 2024, then jumped by 62.84% to -$24.5 million in 2025, then soared by 36.09% to -$15.7 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$15.7 million in Q2 2026, -$71.1 million in Q1 2026, and -$24.5 million in Q4 2025.